

Zbigniew M Szczepiorkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8309922/publications.pdf>

Version: 2024-02-01

122
papers

4,786
citations

172386

29
h-index

98753

67
g-index

128
all docs

128
docs citations

128
times ranked

5575
citing authors

#	ARTICLE	IF	CITATIONS
1	Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. <i>Nature</i> , 2006, 439, 599-603.	13.7	664
2	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue. <i>Journal of Clinical Apheresis</i> , 2013, 28, 145-284.	0.7	520
3	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 83-177.	0.7	441
4	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. <i>Journal of Clinical Apheresis</i> , 2007, 22, 106-175.	0.7	308
5	Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. <i>Journal of Clinical Investigation</i> , 2003, 112, 831-842.	3.9	246
6	Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy. <i>Journal of Immunotherapy</i> , 2011, 34, 382-389.	1.2	153
7	A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. <i>Blood</i> , 2009, 113, 1564-1573.	0.6	150
8	Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN- γ Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 4986-4992.	3.2	100
9	Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. <i>Journal of Clinical Apheresis</i> , 2014, 29, 148-167.	0.7	99
10	Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis. <i>Gastroenterology</i> , 1995, 108, 515-522.	0.6	90
11	Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2003, 36, 1602-1605.	2.9	89
12	Transfusion guidelines: when to transfuse. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 638-644.	0.9	88
13	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. <i>Alzheimer's and Dementia</i> , 2020, 16, 1412-1425.	0.4	82
14	A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide—frozen autologous platelets in healthy volunteers. <i>Transfusion</i> , 2013, 53, 128-137.	0.8	75
15	The new approach to assignment of ASFA categories—Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. <i>Journal of Clinical Apheresis</i> , 2007, 22, 96-105.	0.7	65
16	Red blood cell storage in additive solution—7 preserves energy and redox metabolism: a metabolomics approach. <i>Transfusion</i> , 2015, 55, 2955-2966.	0.8	63
17	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 61-69.	1.8	63
18	Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. <i>Transplantation</i> , 2002, 73, 911-915.	0.5	62

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. <i>Transfusion</i> , 2018, 58, 2129-2138.	0.8	53
20	Red blood cell metabolic responses to refrigerated storage, rejuvenation, and frozen storage. <i>Transfusion</i> , 2017, 57, 1019-1030.	0.8	52
21	CO ₂ -dependent metabolic modulation in red blood cells stored under anaerobic conditions. <i>Transfusion</i> , 2016, 56, 392-403.	0.8	50
22	Safety of platelet transfusion: past, present and future. <i>Vox Sanguinis</i> , 2014, 107, 103-113.	0.7	42
23	Significant reduction in red blood cell transfusions in a general hospital after successful implementation of a restrictive transfusion policy supported by prospective computerized order auditing. <i>Transfusion</i> , 2014, 54, 2640-2645.	0.8	41
24	Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. <i>Cytotherapy</i> , 2013, 15, 255-262.	0.3	39
25	Blood component transfusion and wastage rates in the setting of massive transfusion in three regional trauma centers. <i>Transfusion</i> , 2017, 57, 45-52.	0.8	34
26	Stored red blood cell viability is maintained after treatment with a second-generation S ₂ pathogen inactivation process. <i>Transfusion</i> , 2011, 51, 2367-2376.	0.8	33
27	Balancing risk and benefit. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 74, 1425-1431.	1.1	33
28	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019, 114, 79-94.	0.7	33
29	National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis. <i>Transfusion Medicine Reviews</i> , 2015, 29, 62-70.	0.9	31
30	Errors in patient specimen collection: application of statistical process control. <i>Transfusion</i> , 2008, 48, 2143-2151.	0.8	30
31	Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T cell subpopulations. <i>Transfusion</i> , 2017, 57, 1555-1565.	0.8	28
32	Red blood cell exchange transfusion in two patients with advanced erythropoietic protoporphyria. <i>Transfusion</i> , 2005, 45, 208-213.	0.8	27
33	Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). <i>Transfusion</i> , 2012, 52, 1687-1695.	0.8	27
34	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. <i>Journal of Clinical Apheresis</i> , 2017, 32, 215-223.	0.7	27
35	Category IV indications for therapeutic apheresis—ASFA fourth special issue. <i>Journal of Clinical Apheresis</i> , 2007, 22, 176-180.	0.7	26
36	Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise. <i>Transfusion</i> , 2008, 48, 546-549.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang. <i>Clinical Cancer Research</i> , 2007, 13, 733s-740s.	3.2	25
38	In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. <i>Transfusion</i> , 2013, 53, 972-980.	0.8	25
39	Routine bacterial screening of apheresis platelets on <sc>D</sc>ay 4 using a rapid test: a 4-year single-center experience. <i>Transfusion</i> , 2013, 53, 2307-2313.	0.8	25
40	Assessing the risk of <i>Babesia</i> to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc <i>Babesia</i> Policy Working Group (original report). <i>Transfusion</i> , 2018, 58, 1916-1923.	0.8	25
41	Easier said than done: ABO compatibility and D matching in apheresis platelet transfusions. <i>Transfusion</i> , 2015, 55, 1882-1888.	0.8	24
42	A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. <i>Transfusion Medicine Reviews</i> , 2018, 32, 102-110.	0.9	22
43	Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative. <i>Vox Sanguinis</i> , 2010, 99, 168-173.	0.7	21
44	A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day stored PLT-rich plasma and buffy coat PLTs from the same subjects. <i>Transfusion</i> , 2011, 51, 1241-1248.	0.8	21
45	How do we implement Day 6 and Day 7 platelets at a hospital-based transfusion service?. <i>Transfusion</i> , 2016, 56, 1262-1266.	0.8	21
46	Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report. <i>Transfusion</i> , 2005, 45, 1735-1738.	0.8	20
47	Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. <i>Transfusion</i> , 2011, 51, 1284-1290.	0.8	20
48	Therapeutic plasma exchange in <i>Streptococcus pneumoniae</i>-associated hemolytic uremic syndrome: A case report. <i>Journal of Clinical Apheresis</i> , 2012, 27, 212-214.	0.7	20
49	Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. <i>Cytotherapy</i> , 2008, 10, 30-37.	0.3	19
50	Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy. <i>Transfusion and Apheresis Science</i> , 2013, 49, 185-188.	0.5	19
51	Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. <i>Transfusion</i> , 2006, 46, 523-529.	0.8	18
52	Factors affecting red blood cell storage age at the time of transfusion. <i>Transfusion</i> , 2013, 53, 3110-3119.	0.8	18
53	Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. <i>Alzheimer's and Dementia</i> , 2022, 18, 1314-1324.	0.4	17
54	Low-Density Lipoprotein Reconstituted with Fatty Acid Ethyl Esters as a Physiological Vehicle for Ethyl Ester Delivery to Intact Cells. <i>Alcoholism: Clinical and Experimental Research</i> , 1995, 19, 1265-1270.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 129-137.	2.0	16
56	Overnight, room temperature hold of whole blood followed by 42-day storage of red blood cells in additive solution-7. <i>Transfusion</i> , 2015, 55, 485-490.	0.8	16
57	Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. <i>Transfusion</i> , 2018, 58, 938-942.	0.8	15
58	Frozen Platelets—Development and Future Directions. <i>Transfusion Medicine Reviews</i> , 2020, 34, 286-293.	0.9	15
59	Consensus International Council for Commonality in Blood Banking Automation—International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytotherapy</i> , 2021, 23, 1060-1063.	0.3	15
60	Compatibility of the Abbott IMx Homocysteine Assay with Citrate-Anticoagulated Plasma and Stability of Homocysteine in Citrated Whole Blood. <i>Clinical Chemistry</i> , 2001, 47, 1704-1707.	1.5	14
61	Standards for the Terminology and Labeling of Cellular Therapy Products. <i>Transfusion</i> , 2007, 47, 1319-1327.	0.8	14
62	Rituximab for TTP. <i>American Journal of Hematology</i> , 2005, 80, 87-88.	2.0	13
63	METHOD TO ASSESS FATTY ACID ETHYL ESTER BINDING TO ALBUMIN. <i>Alcohol and Alcoholism</i> , 2006, 41, 240-246.	0.9	13
64	How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. <i>Transfusion</i> , 2007, 47, 1963-1971.	0.8	13
65	The role of physicians in hospital transfusion services. <i>Transfusion</i> , 2006, 46, 862-867.	0.8	11
66	The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection. <i>Transfusion</i> , 2015, 55, 476-484.	0.8	11
67	How do we utilize a transfusion safety officer?. <i>Transfusion</i> , 2015, 55, 2064-2068.	0.8	11
68	Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. <i>American Journal of Hematology</i> , 2022, 97, 256-266.	2.0	11
69	ISBT 128 Implementation Plan for Cellular Therapy Products. <i>Transfusion</i> , 2007, 47, 1312-1318.	0.8	10
70	American Society for Apheresis Guidelines Support Use of Red Cell Exchange Transfusion for Severe Malaria With High Parasitemia. <i>Clinical Infectious Diseases</i> , 2014, 58, 302-303.	2.9	10
71	Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 429-440.	0.6	10
72	Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative. <i>Transfusion</i> , 2011, 51, 2001-2005.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Therapeutic plasma exchange as a steroid-sparing therapy in a patient with limbic encephalitis due to antibodies to voltage-gated potassium channels. <i>Journal of Clinical Apheresis</i> , 2016, 31, 63-65.	0.7	9
74	Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 695-703.	1.3	8
75	Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. <i>Cytotherapy</i> , 2010, 12, 1013-1021.	0.3	8
76	Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital. <i>Journal of Clinical Apheresis</i> , 2015, 30, 359-363.	0.7	8
77	Babesia parasitemia rebound after red blood cell exchange. <i>Journal of Clinical Apheresis</i> , 2017, 32, 276-278.	0.7	8
78	Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. <i>Transfusion</i> , 2018, 58, 461-469.	0.8	8
79	Wastewater-Based SARS-CoV-2 Surveillance in Northern New England. <i>Microbiology Spectrum</i> , 2022, 10, e0220721.	1.2	8
80	Transfusion reaction reporting in the era of hemovigilance: where form meets function. <i>Transfusion</i> , 2011, 51, 2583-2587.	0.8	7
81	Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia. <i>Journal of Clinical Apheresis</i> , 2016, 31, 419-422.	0.7	7
82	The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia. <i>Transfusion</i> , 2017, 57, 2937-2941.	0.8	7
83	Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. <i>Transfusion</i> , 2018, 58, 943-950.	0.8	7
84	Bacterial screening of apheresis platelets with a rapid test: a 113-month single center experience. <i>Transfusion</i> , 2018, 58, 1665-1669.	0.8	7
85	ISBT 128 implementation plan for cellular therapy products. <i>Journal of Clinical Apheresis</i> , 2007, 22, 258-264.	0.7	6
86	Terminology and labeling of cellular products: 1. Standards. <i>Bone Marrow Transplantation</i> , 2007, 40, 1075-1083.	1.3	6
87	Hardwiring patient blood management. <i>Current Opinion in Hematology</i> , 2014, 21, 515-520.	1.2	6
88	Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. <i>Transfusion</i> , 2018, 58, 2184-2191.	0.8	6
89	Terminology and labeling of cellular products 2: Implementation plan. <i>Bone Marrow Transplantation</i> , 2007, 40, 1085-1090.	1.3	5
90	Primum non confundere: whole blood versus apheresis platelet debate continues. <i>Transfusion</i> , 2016, 56, 1254-1257.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Treatment of Bleeding in Severely Thrombocytopenic Patients with Transfusion of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP) Is Safe - Report of a Phase 1 Dose Escalation Safety Trial. Blood, 2016, 128, 1030-1030.	0.6	5
92	Collagen-Induced Whole Blood Platelet Aggregation in Patients Undergoing Surgical Procedures Associated With Minimal to Moderate Blood Loss. American Journal of Clinical Pathology, 1998, 109, 392-398.	0.4	4
93	Between the trash can and the freezer: donor education and the fate of cord blood. Transfusion, 2011, 51, 234-236.	0.8	4
94	Standards for the terminology and labeling of cellular therapy products. Journal of Clinical Apheresis, 2007, 22, 249-257.	0.7	3
95	Successful use of citrate anticoagulant with heparin bolus for excessive clotting during extracorporeal photopheresis. Transfusion, 2012, 52, 2494-2495.	0.8	3
96	Red blood cell alloantibodies: a 45-year historical review at a rural tertiary care center. Transfusion, 2012, 52, 1380-1382.	0.8	3
97	Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia. Journal of Clinical Apheresis, 2018, 33, 436-438.	0.7	3
98	Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization. Journal of Clinical Apheresis, 2018, 33, 310-315.	0.7	3
99	A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity. Transfusion, 2020, 60, 1811-1820.	0.8	3
100	Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services. Archives of Pathology and Laboratory Medicine, 2023, 147, 71-78.	1.2	3
101	Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. Transfusion, 2022, 62, 1619-1629.	0.8	3
102	Multicenter study on in vitro characterization of dendritic cells. Cytotherapy, 2008, 10, 21-29.	0.3	2
103	Plasma exchange in pancreatitis due to hypertriglyceridemia. Transfusion, 2009, 49, 1022-1023.	0.8	2
104	Hematopoietic stem cell transplantation: is ABO match made in heaven?. Transfusion, 2009, 49, 612-614.	0.8	2
105	Persistent increased troponin T in patient with thrombotic thrombocytopenic purpura responsive to treatment. Clinica Chimica Acta, 2010, 411, 890-891.	0.5	2
106	Variations in novel cellular therapy products manufacturing. Cytotherapy, 2020, 22, 337-342.	0.3	2
107	Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma (NHL).. Blood, 2005, 106, 5517-5517.	0.6	2
108	The In Vivo Recovery/Survival and Pharmacokinetic Properties of Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes. Blood, 2016, 128, 2629-2629.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1500-1508.	0.9	2
110	Standardization of cellular therapy terminology, coding and labeling: a review. <i>Cytotherapy</i> , 2022, 24, 577-582.	0.3	2
111	Highlighting oftâ€overlooked granulocyteâ€colonyâ€stimulating factor kinetics. <i>Transfusion</i> , 2016, 56, 1484-1485.	0.8	1
112	Indications for therapeutic apheresis in hematological disorders. <i>Seminars in Hematology</i> , 2020, 57, 57-64.	1.8	1
113	What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CARâ€T therapy. <i>Journal of Clinical Apheresis</i> , 2020, 35, 234-235.	0.7	1
114	Immune Mobilization with Direct In-Vivo Effector Response: Clinical Trial with Favorable Implications for Post-Transplant Outcome.. <i>Blood</i> , 2007, 110, 5120-5120.	0.6	1
115	Passive order auditing associated with reductions in red blood cell utilization: National blood shortage experience. <i>Transfusion</i> , 0, , .	0.8	1
116	Retrograde patient blood flow and rouleaux preventing red blood cell transfusion. <i>Transfusion</i> , 2012, 52, 2284-2284.	0.8	0
117	Immune Mobilization of Autologous Peripheral Blood Progenitor Cells: IL-2 with GM-CSF and G-CSF Results in Effective Mobilization without Delay in Engraftment.. <i>Blood</i> , 2006, 108, 5152-5152.	0.6	0
118	Large Scale Expansion of Activated T Cells: Defining Procedures and Cryopreservation Methods for Clinical Use as Adoptive Cellular Therapy Post-Transplant.. <i>Blood</i> , 2006, 108, 5232-5232.	0.6	0
119	The Critical Requirement of the NKG2D Receptor On CD8+ T Cells in Killing Myeloma Cells.. <i>Blood</i> , 2009, 114, 4733-4733.	0.6	0
120	The Significance of Anti-Platelet Antibodies Associated with Antibiotic Use, A Descriptive Analysis.. <i>Blood</i> , 2009, 114, 4470-4470.	0.6	0
121	Transfusion Service Observations: Red Blood Cell Surname-Antibody Pairings. <i>Ochsner Journal</i> , 2017, 17, 134-135.	0.5	0
122	ISBT 128 in Labeling of Cellular Therapy Products. , 2022, , 469-483.		0